Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-05-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.39.2936PMID 22585689
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

  2015cited by this paper
• EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray

  2010cited by this paper
• An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

  2009cited by this paper
• EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.

  2008cited by this paper
• Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?

  2007cited by this paper
• Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

  2007cited by this paper
• Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins.

  2006cited by this paper
• Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

  2006cited by this paper
• Bladder cancer: epidemiology, staging and grading, and diagnosis.

  2005cited by this paper
• Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

  2003cited by this paper
• Keyhole Limpet Haemocyanin in Experimental Bladder Cancer

  2000cited by this paper
• Keyhole Limpet Hemocyanin for Carcinoma in situ of the Bladder: A Long-Term Follow-Up Study

  2000cited by this paper
• Keyhole Limpet Hemocyanin Immunotherapy of Bladder Cancer: Laboratory and Clinical Studies

  2000cited by this paper
• Efficacy of Prophylactic Immucothel® in Patients Pretreated with Conventional Drugs to Prevent Recurrence of Superficial Bladder Carcinoma

  2000cited by this paper
• Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results.

  2000cited by this paper
• Keyhole limpet hemocyanin (KLH): a biomedical review.

  1999cited by this paper
• Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.

  1996cited by this paper
• Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.

  1995cited by this paper
• Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.

  1995cited by this paper
• Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.

  1995cited by this paper
• Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model.

  1994cited by this paper
• Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).

  1993cited by this paper
• [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].

  1991cited by this paper
• Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.

  1991cited by this paper
• Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.

  1990cited by this paper
• Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.

  1988cited by this paper
• Immunologic reduction of bladder cancer recurrence rate.

  1974cited by this paper
• Immunologic reduction of bladder cancer recurrence rate.

  1974cited by this paper

• Hemocyanins: Microscopic Giants with Unique Structural Features for Applications in Biomedicine

  2025cites this paper
• Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review

  2025cites this paper
• The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

  2024cites this paper
• Assessment of the In Vitro and In Vivo Antitumor Activity of Hemocyanins from Helix aspersa, Helix lucorum, and Rapana venosa in a Graffi Myeloid Tumor Model

  2023cites this paper
• Anti-tumour Activity of Bioactive Compounds Isolated from the Hemolymph and Mucus of the Garden Snail Helix aspersa against a Panel of Human Cancer Cell Lines

  2023cites this paper
• Antitumor Activity of Bioactive Compounds from Rapana venosa against Human Breast Cell Lines

  2023cites this paper
• Selective cytotoxicity and changes in protein expression of T24 bladder carcinoma permanent cell line after treatment with hemocyanins.

  2022cites this paper
• Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.

  2022cites this paper
• Characterization of KLH-driven immune responses in clinical studies: A systematic review

  2022cites this paper
• Antitumor Properties of Epitope-Specific Engineered Vaccine in Murine Model of Melanoma

  2022cites this paper
• Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review

  2021cites this paper
• Anti-tumour drugs of marine origin currently at various stages of clinical trials (review)

  2021cites this paper
• Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19th century

  2021cites this paper
• Intensive therapy with gastropodan hemocyanins increases their antitumor properties in murine model of colon carcinoma.

  2020cites this paper
• Intravesical BCG: where do we stand? Past, present and future

  2019cites this paper
• Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non‐muscle‐invasive disease

  2019cites this paper
• Antitumour activity of Helix hemocyanin against bladder carcinoma permanent cell lines

  2019cites this paper
• Antimicrobial and Immunomodulatory Properties and Applications of Marine-Derived Proteins and Peptides

  2019cites this paper
• A Systematic Review of NMIBC and Intravesical Chemotherapy—Results

  2019cites this paper
• Bio-mining drugs from the sea: High antibiofilm properties of haemocyanin purified from the haemolymph of flower crab Portunus pelagicus (L.) (Decapoda: Portunidae)

  2018cites this paper
• Analysis of a Bladder Cancer Clinical Trial Using a Shared Frailty Model

  2017cites this paper
• Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C

  2017influential citation
• Alternative therapies in patients with non-muscle invasive bladder cancer.

  2017cites this paper
• N-glycan structures of β-HlH subunit of Helix lucorum hemocyanin.

  2017cites this paper
• The efficacy of Apaziquone in the treatment of bladder cancer

  2017cites this paper
• BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG

  2017cites this paper
• Cancer Immunotherapy: Friend or Foe of Mental Health?

  2017cites this paper
• The efficacy of Apaziquone in the treatment of bladder cancer

  2017cites this paper
• Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients

  2017cites this paper
• STABILISING HEMOCYANINS: STEPS TOWARDS FORMULATION OF NEW PROTEIN PHARMACEUTICALS

  2016cites this paper
• Immunomodulatory properties of shellfish derivatives associated with human health

  2016cites this paper
• Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?

  2016cites this paper
• Truncated Escherichia coli thioredoxin induces proliferation of human blood mononuclear cells and production of reactive oxygen species as well as proinflammatory cytokines

  2016cites this paper
• Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin

  2016cites this paper
• Cytotoxic Effects of Rapana venosa Hemocyanin on Bladder Cancer Permanent Cell Lines

  2016cites this paper
• Radula Development in the Giant Key-Hole Limpet Megathura crenulata

  2015cites this paper
• Immune Therapies in Non-Muscle Invasive Bladder Cancer

  2015cites this paper
• Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation

  2015cites this paper
• Molecular cloning, characterization and phylogenetic analysis of an actin gene from the marine mollusk Rapana venosa (class Gastropoda)

  2015cites this paper
• Bladder cancer stem cells: biological and therapeutic perspectives.

  2014cites this paper
• Diverse immune functions of hemocyanins.

  2014cites this paper
• Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development †

  2014cites this paper
• A Novel Immunomodulatory Hemocyanin from the Limpet Fissurella latimarginata Promotes Potent Anti-Tumor Activity in Melanoma

  2014cites this paper
• Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies.

  2014cites this paper
• Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non‐muscle‐invasive bladder cancer treated with intravesical chemotherapy

  2014cites this paper
• Bladder cancer in 2012: Challenging current paradigms

  2013cites this paper
• Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer

  2013cites this paper
• Current intravesical therapy for non-muscle invasive bladder cancer

  2013cites this paper
• Comparison of partial vs radical nephrectomy with regard to other‐cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities

  2013cites this paper